|
|
 |
|
Viewing report
|
|
|
|
Shionogi: Performance, Products, Pipeline and Potential
Espicom Business Intelligence Ltd, March 2010, Pages: 84
Shionogi operates in a number of business fields, and principal among these is its Pharmaceuticals segment. Within this business segment, Shionogi is active in the following therapeutic areas: Infectious Diseases, Metabolic Syndrome, Anticancer, Neurology, Allergy and Circulatory. As part of Shionogi’s Second Medium-Term Management Plan (which began in April 2005, and runs until fiscal 2010), the company is planning to focus research efforts specifically on the treatment of infections, pain and metabolic syndrome.
Within Japan, Shionogi is recognised as one of the leading antibiotics companies and in recent years, Flomox, Flumarin and Vancomycin have all maintained their positions as top sellers in their product categories. However, a contracting antibiotic market and increased competition have impacted negatively on sales. To address this issue Shionogi has developed and launched Finibax (September 2005), and licensed-in Bayer’s Avelox (launched in Japan in December 2005). The company has also revitalised its metabolic syndrome product range with the launches of Crestor and Irbetan, both of which are expected to vie for the position of Shionogi's top-selling product within our forecast period.
To ensure long-term growth, Shionogi has succeeded in developing an encouraging pipeline containing several promising candidate drugs, most notably duloxetine. As one of the smaller pharmaceutical companies in Japan, this has largely been achieved through in-licensing. Shionogi is concentrating resources in the three target areas of infection, pain and metabolic syndrome, with the aim of advancing at least five new chemical compounds to Phase II or more advanced stages by the end of fiscal 2009.
Shionogi has a limited global profile, but has achieved substantial success from out-licensing major products in overseas markets to maximise their sales values and utilise the marketing infrastructures of overseas companies. The US development of Finibax was conducted by Peninsula Pharmaceuticals (now acquired by Johnson & Johnson) and the product was launched during 2007. Shionogi now has the possibility of overseas expansion in the antibiotics field.
This new strategic analysis report Shionogi: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
|
|
|
|
